[ad_1]
Geneva, Switzerland, March 14, 2024 Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO Tim Dyer announced on March 18 We announced that we will be speaking at the Bio-Europe Spring 2024 conference, which will be held from the 20th to the 20th. 2024, Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery in Biology, will also be attending the event.
Mr. Dyer will provide a company update in his presentation and discuss recent developments at Addex.
Presentation details:
Date and time: Tuesday, March 19, 2024
Time: 11:00 – 11:15 CET
Room: 133/134
Venue: Barcelona International Convention Center
Mr. Dyer and Dr. Lütjens will be available for one-on-one meetings during the conference. For more information or to schedule a one-on-one meeting, please contact us through the Conference Online Partner System or email IR@addexpharma.com.
About Adex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of novel orally available small molecule drugs known as allosteric modulators for neurological diseases. Allosteric modulators offer several potential advantages over traditional non-allosteric molecules and may offer improved therapeutic approaches to traditional “orthosteric” small molecules or biological drugs. Adex’s allosteric modulator drug discovery platform targets receptors and other proteins recognized as essential for therapeutic intervention. ADX71149 (mGlu2 positive allosteric modulator or his PAM), Adex’s lead drug candidate, was co-developed with Janssen Pharmaceuticals and is in Phase 2 clinical trials for the treatment of epilepsy. His second clinical program at the company, Zipragrant (mGlu5 negative allosteric modulator, NAM), is being evaluated for future development in post-stroke recovery. Indivior PLC has licensed his Addex’s GABAB PAM program for drug candidate development focused on substance use disorders. Addex is also developing a range of GABAB PAMs for chronic cough, mGlu7 NAMs for stress-related disorders, M4 PAMs for schizophrenia and other forms of psychosis, and mGlu2 NAMs for mild neurocognitive disorders and depression. We are moving forward with our preclinical pipeline. Adex’s shares are listed on the Swiss SIX Exchange, and the American Depositary Shares representing its shares are listed on the Nasdaq Capital Market, trading on each exchange under the ticker symbol “ADXN.”
contact address:
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the use of proceeds from the offering. “may”, “would”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, ” The words “believe,” “estimate,” “anticipate,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain these identifiable words. The forward-looking statements in this press release are based on management’s current expectations and beliefs and may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. It is subject to a number of risks, uncertainties and important factors. Statements contained in this press release are subject to uncertainties, including, without limitation, those related to market conditions. These and other risks and uncertainties are discussed in Adex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 30, 2023. as detailed in the section entitled “Risk Factors”. the final prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future; The forward-looking statements contained in this press release represent Adex Therapeutics’ views only as of the date of this press release and should be relied upon as representing its views as of any subsequent date. Not. Addex Therapeutics expressly disclaims any obligation to update any forward-looking statements.
[ad_2]
Source link
